trending Market Intelligence /marketintelligence/en/news-insights/trending/3B5eO8tjUEu1mR_GghdLjg2 content esgSubNav
Log in to other products

 /


Looking for more?

Contact Us
In This List

Emergent Biosolutions anthrax vaccine facility gets German regulatory approval

Video

Climate Credit Analytics: Linking climate scenarios to financial impacts

Blog

Global M&A Infographic Q1 2021

Blog

Q1 2021 Global Capital Markets Activity: SPAC IPOs, Issuance in Consumer Discretionary Sector Surge

Blog

COVID-19 Impact & Recovery: Private Equity


Emergent Biosolutions anthrax vaccine facility gets German regulatory approval

Emergent BioSolutions Inc. received approval from the German Federal Ministry of Health unit Paul-Ehrlich-Institut for its large-scale manufacturing facility in Lansing, Mich., for the anthrax vaccine BioThrax.

The approval enables Emergent to market BioThrax in Germany.

BioThrax is the only anthrax vaccine licensed by the Paul-Ehrlich-Institut for pre-exposure prophylaxis of anthrax disease. It is also the only anthrax vaccine licensed by the U.S. FDA for both pre-exposure prophylaxis and post-exposure prophylaxis of anthrax disease.